No sting, all win as Scorpion signs lung cancer collaboration with Pierre Fabre

04 Apr 2023
firstwordpharma.com
License out/in
Scorpion Therapeutics and Pierre Fabre have announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two EGFR inhibitorsEGFR inhibitors discovered by the former which could potentially address unmet needs in non-small cell lung cancer (NSCLC), says Scorpion.
STX-721 targets EGFR Exon 20 insertion mutations and has been designed to provide maximised selectivity for the mutant form of the enzyme to avoid inhibition of wild-type EGFR in healthy tissues and minimize the occurrence of skin and gastrointestinal tract toxicities.
STX-241 targets Exon 19 or 21 mutations with the co-occurring C797S mutation, with Scorpion noting that up to 12.5% of patients with NSCLC driven by mutations in Exon 19 or 21 who are treated with an EGFR inhibitor in the front-line setting develop secondary resistance mutations at C797S.
The company adds that there are currently no approved therapeutic options for the significant number of patients that develop this "double mutant" form of NSCLC, creating a significant and growing unmet need.
"Based on (Scorpion’s) preclinical data, we've concluded that STX-721 and STX-241 may present best-in-class product profiles,” said Francesco Hofmann, head of research and development for medical care at Pierre Fabre.
Under the terms of the agreement Scorpion and Pierre Fabre will lead clinical development of STX-721 and STX-241, respectively, with the former retaining commercialisation rights to both assets in the US, Canada and Japan, and Pierre Fabre responsible for commercialization activities in all other territories.
Scorpion SEO Axel Hoos noted that the partnership “should help to expand the reach of our EGFR targeting programs, including markets such as China, where nearly 50% percent of all cases of NSCLC are expected to be EGFR-mutant by 2030.”
The company claims that its pipeline of next-generation EGFR inhibitorsEGFR inhibitors may have the potential to address over 90% of activating mutations in EGFR-mutant NSCLC.
Under the terms of the agreement Pierre Fabre will pay Scorpion a combined $65 million in the form of an upfront payment and the achievement of near-term milestones, with the latter also eligible to receive up to a total of $553 million in potential milestone payments. In addition, Pierre Fabre will pay Scorpion tiered percentage royalties on a licensed product-by-licensed product basis.
Together, Scorpion's next-generation EGFR inhibitorsEGFR inhibitors may have the potential to address over 90 percent of activating mutations in EGFR-mutant NSCLC, potentially providing improved clinical outcomes to thousands of patients globally.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.